参考文献/References:
［1］ RAHMAN M S,WOOLLARD K.Atherosclerosis［J］.Adv Exp Med Biol,2017,1003:121-144.
［2］ KOJIMA Y,WEISSMAN I L,LEEPER N J.The role of efferocytosis in atherosclerosis ［J］.Circulation,2017,135(5):476-489.
［3］ THORP E B.Mechanisms of failed apoptotic cell clearance by phagocyte subsets in cardiovascular disease ［J］.Apoptosis,2010,15(9):1124-1136.
［4］ ARANDJELOVIC S,RAVICHANDRAN K S.Phagocytosis of apoptotic cells in homeostasis ［J］.Nat Immunol,2015,16(9):907-917.
［5］ GHEIBI HAYAT S M,BIANCONI V,PIRRO M,et al.Efferocytosis:molecular mechanisms and pathophysiological perspectives ［J］.Immunol Cell Biol,2019,97(2):124-133.
［6］ ABDOLMALEKI F,FARAHANI N,GHEIBI HAYAT S M,et al.The role of efferocytosis in autoimmune diseases ［J］.Front Immunol,2018,9:1645.
［7］ TAJBAKHSH A,REZAEE M,KOVANEN P T,et al.Efferocytosis in atherosclerotic lesions:malfunctioning regulatory pathways and control mechanisms ［J］.Pharmacol Ther,2018,188:12-25.
［8］ HENSON P M.Cell removal:efferocytosis［J］.Annu Rev Cell Dev Biol,2017,33:127-144.
［9］ TAJBAKHSH A,BIANCONI V,PIRRO M,et al.Efferocytosis and atherosclerosis:regulation of phagocyte function by microRNAs ［J］.Trends Endocrinol Metab,2019,30(9):672-683.
［10］ ELLIOTT M R,RAVICHANDRAN K S.The dynamics of apoptotic cell clearance［J］.Dev Cell,2016,38(2):147-160.
［11］ ELLIOTT M R,KOSTER K M,MURPHY P S.Efferocytosis signaling in the regulation of macrophage inflammatory responses［J］.J Immunol,2017,198(4):1387-1394.
［12］ RAYNER K J.Cell death in the vessel wall:the good,the bad,the ugly ［J］.Arterioscler Thromb Vasc Biol,2017,37(7):e75-e81.
［13］ BOADA-ROMERO E,MARTINEZ J,HECKMANN B L,et al.The clearance of dead cells by efferocytosis［J］.Nat Rev Mol Cell Biol,2020,21(7):398-414.
［14］ YURDAGUL A J,DORAN A C,CAI B,et al.Mechanisms and consequences of defective efferocytosis in atherosclerosis［J］.Front Cardiovasc Med,2018,4:86.
［15］ KUMAR S,BIRGE R B.Efferocytosis［J］.Curr Biol,2016,26(13):R558-R559.
［16］ HAYAT S M G,BIANCONI V,PIRRO M,et al.CD47:role in the immune system and application to cancer therapy［J］.Cell Oncol (Dordr),2020,43(1):19-30.
［17］ DORAN A C,YURDAGUL A J R,TABAS I.Efferocytosis in health and disease［J］.Nat Rev Immunol,2020,20(4):254-267.
［18］ CAI B,THORP E B,DORAN A C,et al.MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation ［J］.Proc Natl Acad Sci USA,2016,113(23):6526-6531.
［19］ CAI B,THORP E B,DORAN A C,et al.MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis［J］.J Clin Invest,2017,127(2):564-568.
［20］ CAI B,KASIKARA C,DORAN A C,et al.MerTK signaling in macrophages promotes the synthesis of inflammation resolution mediators by suppressing CaMKII activity［J］.Sci Signal,2018,11(549):eaar3721.
［21］ YANCEY P G,DING Y,FAN D,et al.Low-density lipoprotein receptor-related protein 1 prevents early atherosclerosis by limiting lesional apoptosis and inflammatory Ly-6C high monocytosis:evidence that the effects are not apolipoprotein Edependent ［J］.Circulation,2011,124(4):454-464.
［22］ YANCEY P G,BLAKEMORE J,DING L,et al.Macrophage LRP-1 controls plaque cellularity by regulating efferocytosis and Akt activation［J］.Arterioscler Thromb Vasc Biol,2010,30(4):787-795.
［23］ TAO H,YANCEY P G,BABAEV V R,et al.Macrophage SR-BⅠ mediates efferocytosis via Src/PI3K/Rac1 signaling and reduces atherosclerotic lesion necrosis［J］.J Lipid Res,2015,56(8):1449-1460.
［24］ YU P,QIAN A S,CHATHELY K M,et al.PDZK1 in leukocytes protects against cellular apoptosis and necrotic core development in atherosclerotic plaques in high fat diet fed ldl receptor deficient mice［J］.Atherosclerosis,2018,276:171-181.
［25］ SADDAR S,CARRIERE V,LEE W R,et al.Scavenger receptor class B type Ⅰ is a plasma membrane cholesterol sensor［J］.Circ Res,2013,112(1):140-151.
［26］ LIU Y,WOODARD P K.Chemokine receptors:key for molecular imaging of inflammation in atherosclerosis［J］.J Nucl Cardiol,2019,26(4):1179-1181.
［27］ AIT-OUFELLA H,KINUGAWA K,ZOLL J,et al.Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice［J］.Circulation,2007,115(16):2168-2177.
［28］ T O ＇TH B,GARABUCZi E,SARANG Z,et al.Transglutaminase 2 is needed for the formation of an efficient phagocyte portal in macrophages engulfing apoptotic cells［J］.J Immunol,2009,182(4):2084-2092.
［29］ 杨後唐.CHl3L1抑制巨噬细胞胞葬对动脉粥样斑块稳定性的影响及机制［D］.上海:海军军医大学,2019.
［30］ THIELENS N M,TEDESCO F,BOHLSON S S,et al.C1q:a fresh look upon an old molecule［J］.Mol Immunol,2017,89:73-83.
［31］ PULANCO M C,COSMAN J,HO M M,et al.Complement protein C1q enhances macrophage foam cell survival and efferocytosis［J］.J Immunol,2017,198(1):472-480.
［32］ 王建茹，张一凡，毛美娇，等.冠心康含药血清通过活化ERK5对ox-LDL负载的巨噬细胞胞葬作用的影响(英文)［J］.暨南大学学报(自然科学与医学版)，2020,41(4):289-302.
［33］ HEO K S,CUSHMAN H J,AKAIKE M,et al.ERK5 activation in macrophages promotes efferocytosis and inhibits atherosclerosis ［J］.Circulation,2014,130(2):180-191.
［34］ GIURISATO E,XU Q,LONARDI S,et al.Myeloid ERK5 deficiency suppresses tumor growth by blocking protumor macrophage polarization via STAT3 inhibition ［J］.Proc Natl Acad Sci USA,2018,115(12):E2801-E2810.
［35］ 王建茹,刘萍.ERK5抑制剂对巨噬细胞胞葬作用及ProS、Axl表达的影响［J］.暨南大学学报(自然科学与医学版),2018,39(2):93-98.
［36］ YE Z M,YANG S,XIA Y P,et al.LncRNA MIAT sponges miR-149-5p to inhibit efferocytosis in advanced atherosclerosis through CD47 upregulation ［J］.Cell Death Dis,2019,10(2):138.
［37］ OKAZAWA H,MOTEGI S,OHYAMA N,et al.Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system ［J］.J Immunol,2005,174(4):2004-2011.
［38］ RUSS A,HUA A B,MONTFORT W R,et al.Blocking "don′t eat me" signal of CD47-SIRPα in hematological malignancies,an in-depth review ［J］.Blood Rev,2018,32(6):480-489.
［39］ KOJIMA Y,VOLKMER J P,MCKENNA K,et al.CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis ［J］.Nature,2016,536(7614):86-90.
［40］ TAJBAKHSH A,GHEIBI HAYAT S M,BUTLER A E,et al.Effect of soluble cleavage products of important receptors/ligands on efferocytosis:their role in inflammatory,autoimmune and cardiovascular disease ［J］.Ageing Res Rev,2019,50:43-57.
［41］ SURESH BABU S,THANDAVARAYAN R A,JOLADARASHI D,et al.MicroRNA-126 overexpression rescues diabetes-induced impairment in efferocytosis of apoptotic cardiomyocytes［J］.Sci Rep,2016,6:36207.
［42］ WEI Y,ZHU M,CORBALAN-CAMPOS J,et al.Regulation of Csf1r and Bcl6 in macrophages mediates the stage-specific effects of microRNA-155 on atherosclerosis ［J］.Arterioscler Thromb Vasc Biol,2015,35(4):796-803.
［43］ WEI Y,NAZARI-JAHANTIGH M,CHAN L,et al.The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis［J］.Circulation,2013,127(15):1609-1619.
［44］ LINTON M F,BABAEV V R,HUANG J,et al.Macrophage apoptosis and efferocytosis in the pathogenesis of atherosclerosis ［J］.Circ J,2016,80(11):2259-2268.
［45］ KAVURMA M M,RAYNER K J,KARUNAKARAN D.The walking dead:macrophage inflammation and death in atherosclerosis ［J］.Curr Opin Lipidol,2017,28(2):91-98.
［46］ GONZALEZ L,TRIGATTI B L.Macrophage apoptosis and necrotic core development in atherosclerosis:a rapidly advancing field with clinical relevance to imaging and therapy ［J］.Can J Cardiol,2017,33(3):303-312.
［47］ YAMAMOTO S,YANCEY P G,ZUO Y,et al.Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis［J］.Arterioscler Thromb Vasc Biol,2011,31(12):2856-2864.
［48］ SHAW P X,HRKK S,TSIMIKAS S,et al.Human-derived anti-oxidized LDL autoantibody blocks uptake of oxidized LDL by macrophages and localizes to atherosclerotic lesions in vivo ［J］.Arterioscler Thromb Vasc Biol,2001,21(8):1333-1339.
［49］ KOJIMA Y,DOWNING K,KUNDU R,et al.Cyclin-dependent kinase inhibitor 2B regulates efferocytosis and atherosclerosis ［J］.J Clin Invest,2019,129(5):2164.
［50］ WILLIAMS J W,MARTEL C,POTTEAUX S,et al.Limited macrophage positional dynamics in progressing or regressing murine atherosclerotic plaques-brief report ［J］.Arterioscler Thromb Vasc Biol,2018,38(8):1702-1710.
［51］ POLYKRATIS A,VAN LOO G,XANTHOULEA S,et al.Conditional targeting of tumor necrosis factor receptor-associated factor 6 reveals opposing functions of Toll-like receptor signaling in endothelial and myeloid cells in a mouse model of atherosclerosis ［J］.Circulation,2012,126(14):1739-1751.
［52］ FRIGGERI A,YANG Y,BANERJEE S,et al.HMGB1 inhibits macrophage activity in efferocytosis through binding to the alphavbeta3-integrin ［J］.Am J Physiol Cell Physiol,2010,299(6):C1267-C1276.
［53］ DE ALMEIDA A C,BARBOSA S M,DE LOURDES RIOS BARJAS-CASTRO M,et al.IFN-β,IFN-γ,and TNF-α decrease erythrophagocytosis by human monocytes independent of SIRP-α or SHP-1 expression ［J］.Immunopharmacol Immunotoxicol,2012,34(6):1054-1059.
［54］ SOLANKI A,BHATT L K,JOHNSTON T P.Evolving targets for the treatment of atherosclerosis ［J］.Pharmacol Ther,2018,187:1-12.
［55］ ZHANG Y,WANG Y,ZHOU D,et al.Angiotensin II deteriorates advanced atherosclerosis by promoting MerTK cleavage and impairing efferocytosis through the AT1R/ROS/p38 MAPK/ADAM17 pathway ［J］.Am J Physiol Cell Physiol,2019,317(4):C776-C787.
［56］ GERLACH B D,MARINELLO M,HEINZ J,et al.Resolvin D1 promotes the targeting and clearance of necroptotic cells ［J］.Cell Death Differ,2020,27(2):525-539.